Advanced Cell Technology, Inc. - Financial and Strategic Analysis Review is an in-depth business, strategic and financial analysis of "Advanced Cell Technology, Inc.". The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.

Advanced Cell Technology, Inc. (ACT) is engaged in the development and commercialization of the human embryonic stem cell technology in the field of regenerative medicine. The company's business is employed in developing and commercializing embryonic stem (ES) cell based technologies and adult stem cell transplantation therapies targeting the heart and other cardiovascular disease therapies. It mainly focuses on its Myoblast program, Retinal pigment epithelium (RPE) program and hemangioblast (HG) cell program. The company is headquartered at Santa Monica in California, the US. In May 2009, the company entered into a licensing agreement with CHA Bio & Diostech Co., Ltd.

And More inside the report…

Recent Developments

Feb 11, 2010: ACT And Collaborators Report Therapeutic Cells Derived From iPS Cells Display Early Aging
Nov 19, 2009: Advanced Cell Technology Files IND With FDA To Intitiate Treatment Of Stargardt’s Macular Dystrophy

Scope

- Provides key company information for business intelligence needs
- The company’s strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
- The opportunities open to the company are considered and its growth potential assessed. Competitive and/or technological threats are highlighted.
- The report contains critical company information – business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
- The report provides detailed financial ratios for the past five years as well as interim ratios for the last fourinterim periods.
- Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Reasons to buy

- A quick "one-stop-shop" to understand the company.
- Enhance business/sales activities by understanding customers’ businesses better.
- Get detailed information and financial & strategic analysis on companies operating in your industry.
- Identify prospective partners and suppliers – with key data on their businesses and locations.
- Capitalize on competitors’ weaknesses and target the market opportunities available to them.
- Compare your company’s financial trends with those of your peers / competitors.
- Scout for potential acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.